Diabetes Mellitus
Conditions
Keywords
T1DM, T2DM, GIP, Glucose-dependent insulinotropic polypeptide, Incretin
Brief summary
The purpose of this study is to determine whether glucose-dependent insulinotropic polypeptide (GIP) has a stabilizing function on the blood glucose
Detailed description
The aim of the study is to investigate the effect of GIP on the glucagon secretion during hyper-, eu- and hypoglycemia in healthy volunteers, patients with type 1 diabetes mellitus and patients with type 2 diabetes mellitus. From this, we will evaluate GIP's role as blood sugar stabilizer.
Interventions
For the first 20 min of the experiment the volunteers will receive GIP at 4 pmol/kg body weight. For the following 40 minutes the volunteers will receive 2 pmol/kg body weight
DRUGPlacebo
copy GIP infusion rates
Sponsors
University Hospital, Gentofte, Copenhagen
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Caucasians with T1DM (diagnosed according to WHO's criteria) without residual beta cell function (arginine test without increase in c-peptide) in treatment with long acting insulin OR * Caucasians with non-insulin treated T2DM (diagnosed according to WHO's criteria) OR * Caucasians without first degree relative with diabetes mellitus, with normal fasting plasma glucose and glucose tolerance along with negative islet and GAD-65 autoantibodies AND * Normal hemoglobin * Informed consent
Exclusion criteria
* Unwillingness to participate or the wish to leave the present study * HbA1c \> 9 % * Liver disease (ALAT or ASAT \> 2 times normal value) * Diabetic nephropathy (serum creatinin \> 130 microM and/or albuminury) * Proliferative diabetic retinopathy (anamnetic) * Atherosclerotic heart disease or heart failure (NYHA group III and IV) * Anemia * Treatment with medicine which cannot be paused for 12 hours * Pregnancy and/or breast feeding * Fasting plasma glucose \> 15 mM on the day of the experiment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The difference in glucagon secretion quantified as the difference in plasma glucagon concentration and incremental baseline-subtracted area under the curve (AUC) for plasma glucagon | -10, 0, 5, 10, 20, 30, 45, 60 and 90 minutes at each visit |
Secondary
| Measure | Time frame |
|---|---|
| The difference between the amount of infused glucose and the insulin responses | will be measured at each visit |
Countries
Denmark
Outcome results
None listed